PriceTargets.com logo

NASDAQ:DMAC - DiaMedica Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.83
  • Forecasted Upside: 159.91 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$9.17 As of 06/14/2021 01:00 AM ET
▲ +0.21 (2.34%)
1 month | 3 months | 12 months
Get New DiaMedica Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMAC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.83
▲ +159.91% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DiaMedica Therapeutics in the last 3 months. The average price target is $23.83, with a high forecast of $38.00 and a low forecast of $14.00. The average price target represents a 159.91% upside from the last price of $9.17.

Buy

The current consensus among 5 investment analysts is to buy stock in DiaMedica Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2021OppenheimerInitiated CoverageOutperform$27.00High
i
3/15/2021Craig HallumBoost Price Target$15.00 ➝ $20.00Medium
i
2/17/2021Roth CapitalInitiated CoverageBuy$38.00Low
i
Rating by E. Piros at Roth Capital
1/4/2021Lake Street CapitalBoost Price TargetBuy$14.00 ➝ $28.00N/A
i
10/30/2020GuggenheimInitiated CoverageBuy$16.00High
i
8/13/2020Maxim GroupReiterated RatingBuyLow
i
Rating by Jason McCarthy at Maxim Group
7/8/2020Maxim GroupInitiated CoverageBuy$14.00Medium
i
5/15/2020Craig HallumBoost Price TargetBuy$10.00 ➝ $15.00High
i
5/15/2020Lake Street CapitalBoost Price TargetBuy$9.00 ➝ $14.00Medium
i
6/20/2019Craig HallumBoost Price TargetBuy$9.00 ➝ $11.00High
i
4/30/2019Dougherty & CoInitiated CoverageBuy ➝ Buy$8.00Low
i
Rating by K. Bauser at Dougherty & Co
3/5/2019Lake Street CapitalInitiated CoverageBuy$9.00High
i
1/3/2019Craig HallumInitiated CoverageBuyN/A
i
(Data available from 6/14/2016 forward)
DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $9.17
$8.87
$9.55

50 Day Range

MA: $8.38
$6.47
$9.91

52 Week Range

Now: $9.17
$3.77
$10.88

Volume

214,980 shs

Average Volume

127,838 shs

Market Capitalization

$172.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaMedica Therapeutics?

The following sell-side analysts have issued reports on DiaMedica Therapeutics in the last twelve months: Craig Hallum, Guggenheim, Lake Street Capital, Maxim Group, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for DMAC.

What is the current price target for DiaMedica Therapeutics?

6 Wall Street analysts have set twelve-month price targets for DiaMedica Therapeutics in the last year. Their average twelve-month price target is $23.83, suggesting a possible upside of 159.9%. Roth Capital has the highest price target set, predicting DMAC will reach $38.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $14.00 for DiaMedica Therapeutics in the next year.
View the latest price targets for DMAC.

What is the current consensus analyst rating for DiaMedica Therapeutics?

DiaMedica Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DMAC will outperform the market and that investors should add to their positions of DiaMedica Therapeutics.
View the latest ratings for DMAC.

What other companies compete with DiaMedica Therapeutics?

Other companies that are similar to DiaMedica Therapeutics include Marinus Pharmaceuticals, AnaptysBio, Clene, Emisphere Technologies, Evolus, Gossamer Bio, Albireo Pharma, Summit Therapeutics, ZIOPHARM Oncology, Applied Therapeutics, Annovis Bio, Clovis Oncology, Catalyst Pharmaceuticals, Inventiva and Bolt Biotherapeutics.

How do I contact DiaMedica Therapeutics' investor relations team?

DiaMedica Therapeutics' physical mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company's listed phone number is 763-312-6755 and its investor relations email address is [email protected] The official website for DiaMedica Therapeutics is www.diamedica.com.